No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 23, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Why Is Biohaven Stock Falling On Thursday?

by TheAdviserMagazine
5 months ago
in Business
Reading Time: 3 mins read
A A
Why Is Biohaven Stock Falling On Thursday?
Share on FacebookShare on TwitterShare on LInkedIn


Biohaven Ltd. (NYSE:BHVN) shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.

The Division of Neurology 1 within FDA’s Office of Neuroscience informed Biohaven that they are extending the PDUFA date for the troriluzole new drug application (NDA) for spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA.

If approved, troriluzole would be the first and only FDA-approved treatment for SCA. Spinocerebellar ataxia is a group of dominantly inherited neurodegenerative disorders characterized by progressive loss of voluntary motor control and atrophy of the cerebellum and brainstem. SCA affects approximately 15,000 people in the United States and 24,000 in Europe and the United Kingdom.

Also Read: Strong Immunoglobulin Reduction Data Positions Biohaven’s BHV-1300 As Potential Autoimmune Therapy

Patients experience significant morbidity, including impaired gait leading to falls, loss of ambulation and progression to a wheelchair, inability to communicate due to speech impairment, difficulty swallowing, and premature death.

The Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.

The FDA did not raise any new concerns in the letter. The FDA’s decision regarding the NDA is expected in the fourth quarter of 2025, compared to the third quarter of 2025, which was expected earlier.

Vlad Coric, Chairman and Chief Executive Officer of Biohaven, stated, “The clinical data presented in the NDA show a highly favorable benefit-risk profile with troriluzole, a once-daily oral pill, slowing disease progression by 50-70%, as measured by the f-SARA scale, and reducing the risk of falls.”

The company recently completed the FDA mid-cycle review meeting and regulatory inspections of Biohaven and key clinical research sites for troriluzole for SCA. The mid-cycle review concluded that there were no previously unidentified major safety concerns, and it does not appear a Risk Evaluation and Mitigation Strategy (REMS) is needed.

In April, the company announced an up to $600 million non-dilutive capital agreement with Oberland Capital Management LLC. The agreement, with $250 million in gross proceeds received on closing on April 30, 2025, is expected to support commercial launch planning in SCA, clinical development activities, and ongoing business operations.

Story Continues

Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518 million.

Analysts at William Blair called the delay surprising, especially given the proximity to the completed mid-cycle review. Biohaven shares are trading down in response to the PDUFA extension and an FDA regulatory landscape with increasing uncertainty given restructuring efforts, as per William Blair.

“We understand the uncertainty here and the perceived increase in regulatory uncertainty, but we remain optimistic that the FDA will show more regulatory flexibility than the EMA given the rare-disease nature of SCA, lack of treatment options for the disease, and troriluzole’s risk/benefit compared to propensity-matched natural history data,” William Blair analysts said.

William Blair reiterates the Outperform rating given the conviction in the likelihood of approval.

Price Action: BHVN stock is down 14.3% at $16.85 at the last check on Thursday.

Read Next:

Image by Tada Images via Shutterstock

Date

Firm

Action

From

To

Mar 2022

Mizuho

Maintains

Buy

Jan 2022

Morgan Stanley

Maintains

Equal-Weight

Nov 2021

Mizuho

Maintains

Buy

View More Analyst Ratings for BHVN

View the Latest Analyst Ratings

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Why Is Biohaven Stock Falling On Thursday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

Tags: BiohavenfallingstockThursday
ShareTweetShare
Previous Post

Diversification through luxury watches? Advisors have thoughts

Next Post

IAI eyes takeover of Spacecom

Related Posts

edit post
NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

by TheAdviserMagazine
October 23, 2025
0

 Zohran Mamdani was attacked over his thin resume, Republican Curtis Sliwa strove to prove his seriousness as a candidate and...

edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

by TheAdviserMagazine
October 23, 2025
0

Indian companies increased their reliance on the debt money market for their short-term working capital needs with the issuance value...

edit post
Israeli joint venture wins huge Indian army rifle deal

Israeli joint venture wins huge Indian army rifle deal

by TheAdviserMagazine
October 23, 2025
0

The Indian Army is procuring 425,000 CQB carbine assault rifles from PLR Systems, a joint venture between Israel Weapons...

edit post
Stock Market Today: Dow Jones Index Gains As Tesla Dives On Earnings (Live)

Stock Market Today: Dow Jones Index Gains As Tesla Dives On Earnings (Live)

by TheAdviserMagazine
October 23, 2025
0

The Dow Jones Industrial Average and the other major stock indexes reversed from premarket losses and ventured into positive ground...

edit post
United Bankshares GAAP EPS of alt=

United Bankshares GAAP EPS of $0.92 beats by $0.11, revenue of $323.32M beats by $13.52M

by TheAdviserMagazine
October 23, 2025
0

United Bankshares press release (NASDAQ:UBSI): Q3 GAAP EPS of $0.92 beats by $0.11. Revenue of $323.32M (+23.3% Y/Y) beats by...

edit post
U.S. national debt hits  trillion and Washington is ‘numb to our own dysfunction,’ budget committee warns

U.S. national debt hits $38 trillion and Washington is ‘numb to our own dysfunction,’ budget committee warns

by TheAdviserMagazine
October 23, 2025
0

America’s debt burden has hit $38 trillion. In fact, at the time of writing, it is $19 billion over that...

Next Post
edit post
IAI eyes takeover of Spacecom

IAI eyes takeover of Spacecom

edit post
There Are Only Two Major Opportunities For OMS Vendors To Win New Deals Right Now

There Are Only Two Major Opportunities For OMS Vendors To Win New Deals Right Now

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
Glassnode identifies concentrated Bitcoin selling amid market consolidation

Glassnode identifies concentrated Bitcoin selling amid market consolidation

0
edit post
Why The Smartest Are Not The Richest

Why The Smartest Are Not The Richest

0
edit post
Shell: Energieriese nach monatelanger Seitwärtsphase im Aufwind!

Shell: Energieriese nach monatelanger Seitwärtsphase im Aufwind!

0
edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

0
edit post
How to Prepare and Plan for Retirement

How to Prepare and Plan for Retirement

0
edit post
UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

0
edit post
Glassnode identifies concentrated Bitcoin selling amid market consolidation

Glassnode identifies concentrated Bitcoin selling amid market consolidation

October 23, 2025
edit post
NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’

October 23, 2025
edit post
Why The Smartest Are Not The Richest

Why The Smartest Are Not The Richest

October 23, 2025
edit post
Corporate debt surge: Commercial paper issuances hit highest since April

Corporate debt surge: Commercial paper issuances hit highest since April

October 23, 2025
edit post
UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

UK startup Mondra lands €11.4M to help food industry manage climate and supply chain volatility

October 23, 2025
edit post
Israeli joint venture wins huge Indian army rifle deal

Israeli joint venture wins huge Indian army rifle deal

October 23, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Glassnode identifies concentrated Bitcoin selling amid market consolidation
  • NYC mayoral candidates turn on each other in final debate: ‘Zohran, your resume could fit on a cocktail napkin. And, Andrew, your failures could fill a public school library in New York City’
  • Why The Smartest Are Not The Richest
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.